Century Living Acquires Site for Luxury Apartments in Denver's LoHi Neighborhood Accessibility Statement Skip NavigationHigh-end, amenitized project will include a pool, sun deck and select loft unitsDENVER, March 10, 2026 /PRNewswire/ -- Century Communities, Inc. (NYSE: CCS)—a top national homebuilder, industry leader in online home sales, and featured on America's Most Trustworthy Companies and World's Most Trustworthy Companies by Newsweek—announced that Century Living, the Company's multi-family arm, ac ...

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or ...

Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Robert F. Abbott has been investing his family's accounts since 1995, and in 2010 added options, main ...

About this content We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. This is content that excites and engages motivated private investors. The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies. Use of technology Proactive has always been a f ...

Treasury yields were little changed as the Trump administration said the war in Iran is near an end but not quite there yet. ...

Core Insights - Citius Oncology announced positive topline results from a Phase 1 clinical trial of LYMPHIR in combination with pembrolizumab for patients with relapsed or refractory gynecologic cancers, indicating potential for enhanced efficacy of immune checkpoint inhibitors [1][2] - The study showed a 24% objective response rate (ORR) and a 48% clinical benefit rate (CBR) among evaluable patients, suggesting promising anti-tumor activity [1] Company Overview - Citius Oncology is focused on developing and commercializing novel targeted oncology therapies, with LYMPHIR being a key product approved for treating relapsed or refractory cutaneous T-cell lymphoma [1][2] - The company has robust intellectual property protections, including orphan drug designation and pending patents for immuno-oncology applications, which strengthen its competitive position in the market [2] Clinical Study Details - The Phase 1 study was led by the University of Pittsburgh and involved 25 evaluable patients, with no unexpected safety signals reported [1] - LYMPHIR was administered intravenously in escalating doses alongside pembrolizumab, with the aim of establishing a recommended dose for future studies [1] Market Potential - The initial market for LYMPHIR is estimated to exceed $400 million and is considered underserved by existing therapies, indicating significant growth potential [2] - The combination therapy approach with LYMPHIR and pembrolizumab may address the unmet needs in treating recurrent or metastatic gynecologic cancers, which have limited treatment options [1][2]

Core Viewpoint - NewtekOne, Inc. has launched the Newtek Seven Day Business Loan™, offering business loans up to $350,000 funded within seven days, structured over a ten-year repayment period with favorable borrowing costs compared to alternatives like merchant cash advances [1][3] Group 1: Product Offering - The Newtek Seven Day Business Loan allows approved borrowers to access funds quickly, with a total borrowing cost that is more favorable than other quick funding options [1] - The loan is secured with collateral and designed to avoid balloon payment risks, providing predictable monthly payments for independent business owners [3] Group 2: Technology Integration - Newtek Bank utilizes the internally developed NewTracker loan processing system powered by AI to achieve seven-day loan processing times [2] - AI assists in the underwriting process by analyzing historical financials, projecting future cash flows, and reviewing corporate documents, enhancing the borrower experience by reducing fees and closing times [2][3] Group 3: Business Growth and Efficiency - The incorporation of AI has allowed Newtek Bank to triple the number of loans closed over the past three years without increasing headcount in the loan closing staff [3] - The company emphasizes its technological advantage in banking, which improves operating efficiency and profitability while maintaining credit quality in lending decisions [3] Group 4: Market Position and Future Outlook - NewtekOne has opened 9,000 deposit accounts in Q4 2025, bringing the total to 35,000, showcasing its ability to operate digitally without traditional banking methods [3] - The company believes that technology-oriented banks will need to leverage advanced tools for efficient customer service and prudent credit underwriting in the future [3]

Core Insights - The transaction is expected to approximately triple NEXGEL's annual revenue to about $35 million and make the Company immediately profitable upon closing [1][7] - NEXGEL is acquiring a diversified suite of 6 established regenerative biomaterial products, most with existing insurance reimbursement, along with three new product 510(k) filings planned for 2026, 2027, and 2028 [1][2] - An experienced commercial team is expected to join NEXGEL, significantly expanding the Company's sales reach and operational capabilities [1][2] Financial Impact - The transaction represents a significant milestone in NEXGEL's history, expected to triple its revenue base and establish immediate profitability [1][7] - The Company anticipates closing on approximately $14.9 million in additional financing during the first quarter of 2026 or early in the second quarter of 2026 [3] Product Portfolio - The portfolio includes 6 commercial-stage regenerative biomaterial products focused on tendon repair, skin grafts, and bone growth, all within the rapidly growing regenerative biomaterials market [2][7] - These products have over a decade of clinical use and demonstrated clinical utility, providing a stable and diversified revenue foundation [2][7] Strategic Rationale - The acquisition is seen as a transformative moment for NEXGEL, positioning it as a growing force in medical technology with established products and strong reimbursement dynamics [6][8] - The transaction allows for strategic synergies by combining and scaling complementary biomaterials and hydrogel technologies across multiple industry verticals [7][8] Team and Expertise - An accomplished commercial and scientific team is expected to join NEXGEL, significantly enhancing the Company's sales organization and domain expertise in regenerative biomaterials [7][8]

SUNNYVALE, Calif. & SINGAPORE--(BUSINESS WIRE)--KNOREX Ltd. (NYSE American: KNRX) ("KNOREX†or the "Company†), a leading provider of AI-driven programmatic advertising solutions, today announced the full-scale commercial deployment of major enhancements to KNOREX KAIROSâ"¢ after more than six months of selective deployments, the Company's proprietary artificial intelligence decisioning infrastructure powering bid optimization and performance modeling within the KNOREX XPOâ"¢ platform. The upgraded. ...

Core Insights - Jaguar Uranium Corp. is advancing its uranium exploration strategy in Argentina and Colombia for 2026, aiming to define an initial mineral resource while leveraging historic exploration data [1][10] Argentina - Flagship Exploration Focus - In Argentina, the company will prioritize exploration at the Laguna Salada Uranium Project and the historic Huemul Uranium Mine, with Laguna Salada covering approximately 230,000 hectares, making it one of the largest uranium exploration land packages in the country [2] - The Environmental Impact Assessment (EIA) for the Guanaco area within Laguna Salada has been approved, allowing exploration activities to commence [8] Exploration Activities - Fieldwork at Guanaco is set to begin soon, targeting near-surface uranium mineralization for bulk exploration [3] - At Huemul, the company is preparing to submit its Environmental Baseline Study to initiate its exploration program, as it is a historically significant uranium district [4] Colombia - Large Exploration Property with Historic Drilling - The Berlin Project in Colombia is a substantial uranium exploration property with significant historic drilling completed, and a large portion of the historic drill core remains available for analysis [5] - The company plans to systematically review and re-analyze the historic core alongside existing geological data to advance the project toward defining an initial mineral resource [6] Strong Jurisdictional Support - The company is engaging constructively with local and provincial governments in Argentina and Colombia, reflecting the growing recognition of uranium's strategic importance in the global nuclear energy sector [7] Financial Position - Jaguar Uranium Corp. is financially well-positioned, with current cash resources expected to support planned exploration activities for approximately two years [9] - The company has the backing of significant industry shareholders, including IsoEnergy Ltd., enhancing its financial stability [9] Executive Commentary - The Executive Chairman emphasized the unique uranium portfolio controlled by the company, which includes district-scale land packages and historic exploration data, aiming to accelerate the path to discovery and resource definition [10]